Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb:55:101692.
doi: 10.1016/j.mcp.2020.101692. Epub 2020 Dec 28.

Nanobodies, the potent agents to detect and treat the Coronavirus infections: A systematic review

Hamed Zare  1 , Hossein Aghamollaei  2 , Maryam Hosseindokht  3 , Mohammad Heiat  4 , Ali Razei  5 , Hamid Bakherad  6
Affiliations

Nanobodies, the potent agents to detect and treat the Coronavirus infections: A systematic review

Hamed Zare et al. Mol Cell Probes. 2021 Feb.

Abstract

The newly emerged coronavirus (SARS-CoV-2) continues to infect humans, and no effective treatment has yet been found. Antibody therapy is one way to control infection caused by COVID-19. However, the use of classical antibodies raises complex issues. Heavy chain antibodies (HCAbs) are single-domain antibodies derived from the Camelidae family. The variable part of these antibodies (Nanobodies or VHH) has interesting properties such as small size, cost-effective production, and good tissue permeability, causing VHH to be regarded as an antiviral therapeutics. However, the small size of nanobodies may lead to low antigen binding affinity and rapid renal clearance. In this systematic review, the application of nanobodies in the treatment of COVID-19 infection and other similar infections (MERS and SARS) was reviewed.

Keywords: COVID-19; Nanobodies; SARS-CoV-2; VHH.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
A schematic picture of nanobody mechanisms. (a) By binding nanobodies to a localization signal (LS), the protein of interest (POI) can be enriched at a specific cellular site, such as mitochondria, (b) Nanobodies can perform a direct inhibitory effect and prevent from a protein activity, (c) Nanobodies can be used to target a for enzymatic degradation, (d) Fusion between the nanobody and the fluorescent protein (FP) results in the formation of a chromobody. POI can be visualized and traced using this chromobody.
Fig. 2
Fig. 2
Application of nanobodies in diagnosis and treatment of diseases.
Fig. 3
Fig. 3
Systematic review flow chart of the first literature search according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines.
See this image and copyright information in PMC

References

    1. Cao X. COVID-19: immunopathology and its implications for therapy. Nat. Rev. Immunol. 2020;20(5):269–270. - PMC - PubMed
    1. Martina B.E., Haagmans B.L., Kuiken T., Fouchier R.A., Rimmelzwaan G.F., Van Amerongen G., Peiris J.M., Lim W., Osterhaus A.D. SARS virus infection of cats and ferrets. Nature. 2003;425(6961) 915-915. - PMC - PubMed
    1. Memish Z.A., Cotten M., Meyer B., Watson S.J., Alsahafi A.J., Al Rabeeah A.A., Corman V.M., Sieberg A., Makhdoom H.Q., Assiri A. Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia. Emerg. Infect. Dis. 2013;20(6):1012. 2014. - PMC - PubMed
    1. Sanders J.M., Monogue M.L., Jodlowski T.Z., Cutrell J.B. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. Jama. 2020;323(18):1824–1836. - PubMed
    1. Campos E.V., Pereira A.E., de Oliveira J.L., Carvalho L.B., Guilger-Casagrande M., de Lima R., Fraceto L.F. How can nanotechnology help to combat COVID-19? Opportunities and urgent need. J. Nanobiotechnol. 2020;18(1):1–23. - PMC - PubMed

Publication types

Substances